Outcome of the Board Meeting held on August 07, 2025
DMCC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of DMCC Speciality Chemicals approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. Standalone net sales came in at Rs. 12,702.32 lakhs, up sharply from Rs. 8,531.81 lakhs in the same quarter last year. Net profit surged to Rs. 775.31 lakhs (vs. Rs. 138.58 lakhs in Q1 FY25), with basic EPS of Rs. 3.11 (vs. Rs. 0.56). The board also re-appointed Dr. Janaki Ashwin Patwardhan as a Non-Executive Independent Director for a second five-year term, effective May 21, 2026 to May 20, 2031, subject to shareholder approval. The statutory auditors issued an unmodified limited review opinion on the results.
Strong year-on-year growth in both revenue (~49%) and net profit (~460%) suggests significantly improved operating performance in Q1 FY26, which is positive for shareholders. The re-appointment of an existing independent director for another term is a routine governance matter and unlikely to materially impact the stock.